Literature DB >> 10501242

AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus.

D Matteucci1, M Pistello, P Mazzetti, S Giannecchini, P Isola, A Merico, L Zaccaro, A Rizzuti, M Bendinelli.   

Abstract

The feline immunodeficiency virus (FIV) provides an excellent model system for AIDS vaccination studies. In the present experiments we investigated the immunogenicity and the protective activity of two inactivated vaccines prepared from a primary virus isolate. One vaccine was composed of whole virus inactivated with paraformaldehyde and then purified (WIV) and the other of viral proteins extracted with Tween-ether (TEV). Both vaccines elicited robust antiviral responses, but neither conferred appreciable levels of resistance against systemic challenge with the homologous virus. In addition, we tested whether the WIV vaccine, that had appeared more immunogenic, could protect against nontraumatic intravaginal exposure to FIV-infected cells. Although the proportions of control and vaccinated animals that became infected following mucosal challenge were similar, the vaccinees had significantly lower viral burdens than the controls, thus suggesting that immunisation with the WIV vaccine had limited FIV replication following intravaginal challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501242     DOI: 10.1016/s0264-410x(99)00189-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

Review 4.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

Review 5.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems.

Authors:  Kristina E Howard; Mary Jo Burkhard
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

10.  A novel method for producing target cells and assessing cytotoxic T lymphocyte activity in outbred hosts.

Authors:  Francesca Bonci; Elisa Zabogli; Francesca Conti; Antonio Merico; Giulia Freer; Mauro Bendinelli; Mauro Pistello
Journal:  BMC Biotechnol       Date:  2009-03-11       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.